Insilico Medicine Launches Groundbreaking AI-Driven Drug Trial for Pulmonary Fibrosis
Insilico Medicine has initiated the world's first Phase III clinical trial for a drug developed using generative AI technology, targeting idiopathic pulmonary fibrosis (IPF). This pioneering trial marks a significant milestone in the integration of artificial intelligence in pharmaceutical development.